steroid-refractory

$Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

By MedXY 08/27/2026

This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT's potential as a safe and effective treatment option.

$Limited Success: Third-Line Therapy Yields Modest Responses in Steroid-Refractory aGvHD with GI Involvement$

Hematology-Oncology news

Limited Success: Third-Line Therapy Yields Modest Responses in Steroid-Refractory aGvHD with GI Involvement

By MedXY 04/03/2026

The CHRONOS study reveals that third-line therapy for steroid- and ruxolitinib-refractory aGvHD with GI involvement achieves only 36% overall response at Day 28, with concerning durability issues and high mortality rates in this heavily pretreated European cohort.

$Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis$

Gastroenterology Specialties

Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis

By MedXY 08/17/2025

Cyclosporin demonstrated high clinical response rates in adults with severe steroid-refractory ulcerative colitis, allowing over half to avoid colectomy and highlighting its role as an effective rescue therapy.

$Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial$

Clinical Updates news Specialties Transplantation

Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial

By MedXY 08/07/2025

The REACH3 study confirms ruxolitinib's superiority over best available therapy in steroid-refractory/dependent chronic GVHD, demonstrating sustained efficacy, improved failure-free survival, and a manageable long-term safety profile over three years.